ClinicalTrials.gg
CompletedNCT03450720Updated Mar 19, 2018

Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis

A Phase 1 interventional study of GLPG2737 single dose in Cystic Fibrosis, sponsored by Galapagos NV. Completed at 1 site in Belgium. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-19.

Sponsored by Galapagos NV · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jun 2017, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 118 studies in Cystic Fibrosis with a site in Belgium — 6 open to participants now, 9 under way, 2 of them phase 3. Cystic Fibrosis · Belgium.

Enrollment
96th of 101
6 · median 78
Started
2017
with 10 others
Phase 1
5 of 118
none open now
Registered
70th of 118
by date
Lead sponsor
6 of 118
Galapagos NV

Among the 118 studies in Cystic Fibrosis with a site in Belgium, this one is the 96th largest by enrollment of the 101 interventional ones that give a count, is one of 11 that started in 2017, is one of 5 in phase 1, and was the 70th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

6 of the 118 studies in Cystic Fibrosis with a site in Belgium are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Cystic Fibrosis with a site in Belgium, or all of them as a file.
02

Study summary

This is a single dose, open label study in adult male subjects with cystic fibrosis to investigate the pharmacokinetics, safety and tolerability of GLPG2737.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subject ≥18 years of age on the day of signing the form (ICF).
  • A confirmed clinical diagnosis of CF.
  • Two mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene belonging to class I and/or class II and/or class III (documented in the subject's medical record or CF registry).
  • Weight ≥40 kg.
  • Exocrine pancreatic insufficiency (documented in the subject's medical record).
  • Stable concomitant medication regimen for at least 2 weeks prior to study drug administration.
  • (FEV1) ≥40% of predicted normal for age, gender and height at screening (pre- or postbronchodilator).

Exclusion criteria

Exclusion Criteria:

  • History of unstable or uncontrolled chronic disease that makes the subject unsuitable for inclusion in the study in the opinion of the investigator.
  • Unstable pulmonary status or respiratory tract infection (including rhinosinusitis) requiring a change in therapy within 2 weeks prior to study drug administration.
  • History of hepatic cirrhosis with portal hypertension (e.g.,signs/symptoms of splenomegaly, esophageal varices).
  • Use of CFTR modulator therapy (e.g., lumacaftor or ivacaftor) within 2 weeks prior to study drug administration.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    GLPG2737 single dose.

    Single dose of GLPG2737 oral suspension.

    Drug: GLPG2737 single dose

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of GLPG2737and its metabolite.

    To characterize the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.

    Time frame: Between day 1 pre-dose and 48 hours post-dose.

  2. Time of occurrence of Cmax for GLPG2737(tmax)

    To determine PK parameters of GLPG2737 and its metabolite after given a single oral dose in CF subjects.

    Time frame: Between day 1 pre-dose and 48 hours post-dose.

  3. Plasma concentration observed at 24 hours post-dos (C24h)

    To assess PK parameters of GLPG2737 and its metabolite after given a single oral dose in CF subjects.

    Time frame: Between day 1 pre-dose and 48 hours post-dose.

  4. Area under the plasma concentration-time curve for GLPG2737 (AUC0-24h)

    To determine the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.

    Time frame: Between day 1 pre-dose and 48 hours post-dose.

  5. Area under the plasma concentration-time curve from time zero until 48 hours post-dose (AUC0-48h)

    To determine the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.

    Time frame: Between day 1 pre-dose and 48 hours post-dose.

  6. Terminal plasma elimination rate constant (ke)

    To determine the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.

    Time frame: Between day 1 pre-dose and 48 hours post-dose.

  7. Apparent terminal elimination half-life ( t1/2)

    To determine the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.

    Time frame: Between day 1 pre-dose and 48 hours post-dose.

Secondary outcomes

  1. Number of subjects with adverse events.

    To determine the safety and tolerability of GLPG2737 after a single oral dose in CF subjects.

    Time frame: Between screening and 15 days post-dose

07

Study locations

1 site
  • UZ KU Leuven
    Leuven, Belgium
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Aug 2017, 1 month.

Of 39 industry-sponsored phase 1 interventional studies under Cystic Fibrosis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 62 studies reached it within 10 months; a quarter within 5 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2018
First posted
Mar 1, 2018
StartActual
Jun 28, 2017
Primary completionActual
Aug 16, 2017
CompletionActual
Aug 16, 2017
Last update
Mar 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03450720
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Mar 1, 2018
Start date
Jun 28, 2017
Primary completion
Aug 16, 2017
Completion
Aug 16, 2017
Last update
Mar 19, 2018

Study contacts

Olivier Van de Steen, MD MBA
study director · Galapagos NV

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG-2737

Start the discussion